ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9259
-0.34%
Brent Oil
83.575
0.54%
Bitcoin
64,567.85
0.89%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. USOTC
  6. Amarantus Bioscience Holdings Inc (CE) (AMBS)

  7. Amarantus Bioscience Holdings Inc (CE) (AMBS) Noticias

AMBS

Amarantus Bioscience (CE) (AMBS)

Amarantus Bioscience Holdings Inc (CE)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:AMBS
FechaHoraFuenteTítuloSímboloCompañía
09/09/202213:20Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
18/04/202215:18Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/10/202005:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
10/07/202014:03InvestorsHub NewsWireTodos Medical Expands Extraction Reagent and ANDiS 350 Extraction Automation Capacity to Support COVID-19 Testing in the USAUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
30/01/202008:42InvestorsHub NewsWireAmarantus Acquires Majority Interest in CBD Wellness Company HemporiUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
10/01/202005:52Edgar (US Regulatory)Withdrawal of Offering Statement Under Regulation a (1-a-w)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/01/202016:13Edgar (US Regulatory)Amended Registration a Offering Under the Securities Act of 1933 (1-a/a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/01/202016:06Edgar (US Regulatory)Registration a Offering Under the Securities Act of 1933 (1-a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
04/12/201907:17InvestorsHub NewsWireAmarantus Sub Elto Pharma Gets Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson's DiseaseUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
24/10/201908:52InvestorsHub NewsWireAmarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic ProductsUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
28/05/201908:51InvestorsHub NewsWireAmarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Legal Hemp IndustryUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
07/01/201907:00InvestorsHub NewsWireAmarantus Provides 2019 RoadmapUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
28/11/201806:30InvestorsHub NewsWireCoeptis Pharma Enters into Agreement to Acquire Elto PharmaUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
20/07/201806:31InvestorsHub NewsWireAmarantus Provides Corporate UpdateUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/07/201807:00InvestorsHub NewsWireMANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published inUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
11/06/201806:00InvestorsHub NewsWireMANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal ModelUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
07/06/201807:17InvestorsHub NewsWireAmarantus Provides Update on Elto Pharma Capital Formation PlanUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
05/06/201807:11InvestorsHub NewsWireMANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science AdvancesUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
30/05/201807:00InvestorsHub NewsWireAmarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
24/05/201810:00InvestorsHub NewsWireAmarantus to Present at LD Micro and The Reg A ConferenceUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
22/05/201805:00InvestorsHub NewsWireAmarantus Retains Weild & Co. to Advise on JOBS Act FundingUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
21/05/201806:58InvestorsHub NewsWireMANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal..USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
11/05/201806:00InvestorsHub NewsWireAmarantus Provides Business OverviewUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
04/05/201807:16InvestorsHub NewsWireAmarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood DiagnosticUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
03/05/201808:15InvestorsHub NewsWireMANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's NewUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
01/05/201809:30InvestorsHub NewsWireElto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairm...USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
30/04/201806:00InvestorsHub NewsWireElto Pharma Appoints Paula Trzepacz, MD as Chief Medical Advisor Ex-Lilly Sr. Medical Fellow in Neurosciences to leadUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
23/04/201807:00InvestorsHub NewsWireCutanogen Appoints Richard Kagan, MD as Chief Medical Advisor Emeritus Chief of Staff of Shriners Burns Hospital - Cincinnati...USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
16/04/201806:30InvestorsHub NewsWireAmarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test ProgramUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/04/201811:40InvestorsHub NewsWireAmarantus to Present at The Microcap Conference in NYCUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
 Showing the most relevant articles for your search:USOTC:AMBS

Su Consulta Reciente

COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
ADDYY
Adidas (QX)
AMEX
SPY
SPDR S&P 500
FX
EURMXN
Euro vs MXN
FX
USDMXN
US Dollar vs MXN
COIN
BTCUSD
Bitcoin
CCOM
US30
US 30
NASDAQ
AMZN
Amazon.com
NYSE
AXP
American Express
NYSE
DIS
Walt Disney
AMEX
XLF
Financial Select Sector
USI
USTECH100
US Tech 100
NASDAQ
NVDA
NVIDIA
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados